No Data
No Data
Changes in Hong Kong stocks | Zaiding Pharmaceutical (09688) opened up nearly 5%, net product revenue of US$87.1 million in the first quarter increased 39% year-on-year
Zaiding Pharmaceutical (09688) opened nearly 5% higher in early trading. As of press release, it rose 4.86% to HK$13.8, with a turnover of HK$1,357,900.
Zai Lab Q1 Loss Widens Despite Higher Revenue
Zai Lab (HKG:9688) posted a net loss of $53.5 million for the first quarter, compared with a loss of $49.1 million in the year-ago quarter, according to a Thursday filing on the Hong Kong bourse. The
Zaiding Pharmaceutical's net product revenue of US$87.1 million in the first quarter increased 39% year-on-year
Zaiding Pharmaceutical (09688) announced that total net product revenue for the first quarter of 2024 was US$87.1 million, up 39% year on year; 43% year on year based on fixed exchange rate (CER); R&D expenses were US$54.6 million, up 12.58% year on year; and cash reserves as of March 31, 2024 were US$750.8 million. According to the announcement, the increase in product revenue was mainly due to an increase in sales volume, including Wei Weijia's launch in September last year, and a reduction in sales rebates given to dealers due to price cuts for some products due to inclusion in China's National Medical Insurance Drug Catalogue (NRDL).
Zaiding Pharmaceutical (09688)'s net product revenue of US$87.1 million in the first quarter increased 39% year-on-year
Zaiding Pharmaceutical (09688) announced that the total net product revenue for the first quarter of 2024 was US$87.1 million...
Zaiding Pharmaceutical (09688.HK): Product revenue of US$87.1 million in the first quarter increased 39% year-on-year
Gelonghui, May 9 | Zaiding Pharmaceutical (09688.HK) announced financial results for the first quarter of 2024. Product revenue for the first quarter of 2024 was US$87.1 million and US$62.8 million for the same period of 2023, an increase of 39% year-on-year, and 43% year-on-year increase according to CER. The increase in product revenue is mainly due to an increase in sales volume, including Wei Weijia's launch in September last year, and a reduction in sales rebates given to dealers due to price cuts for some products due to inclusion in China's National Medical Insurance Drug List (NRDL). R&D expenses for the first quarter of 2024 were $54.6 million, 202
Zai Lab 1Q Loss/Shr 5c >ZLAB
Zai Lab 1Q Loss/Shr 5c >ZLAB